Clinical Trial Update: Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

View source ↗

Summary

A recruiting clinical trial evaluating how endocrine therapy, menstrual cycle phases, PAM50 subtype, and Ki67 influence treatment decisions in hormone receptor-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer | Status: RECRUITING